Latest news

• ViiV builds case for switching to its two-drug HIV combinations

  ViiV needs to convince patients, prescribers and payers that there is a real benefit to that approach if it is to challenge drugs like Gilead’s three-drug Biktarvy

• ViiV bags EU okay for new two-drug HIV therapy

  bictegravir/emtricitabine/tenofovir alafenamide) product.

• Shingrix lifts GSK in Q1, but two more vaccines are culled

  such as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has started to chip away at growth levels.

• Dovato approval key for Glaxo in HIV treatment

  This gives the company the upperhand over its chief rival, Gilead, which has come to dominate this segment since it launched Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide [TAF]) in February 2018.

• GSK’s says depot HIV injection works over three years

  drug tablet Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).